Text Size

Effects of Angiotensin Receptor Antagonist on Prohibiting Cardiovascular Events on Hemodialysis Patients

This study has been completed.
Sponsor:
Information provided by:
Saitama Medical University
ClinicalTrials.gov Identifier:
NCT00530595
First received: September 13, 2007
Last updated: September 14, 2007
Last verified: September 2007
History of Changes
  Purpose

Cardiovascular disease is a leading cause of mortality in patients on hemodialysis therapy (HD), accounting for 30 to 50% of all death. Although angiotensin receptor blockers (ARBs) are effective for patients with diabetes and chronic kidney disease in reducing or preventing cardiovascular diseases, there has been no decisive study that demonstrated treatment with ARBs is effective in patients on HD.


Condition Intervention
Cardiovascular Disease
 Drug: candesartan or valsartan or losartan

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

MedlinePlus related topics: Dialysis
U.S. FDA Resources

Further study details as provided by Saitama Medical University:

  Eligibility

Ages Eligible for Study:   30 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 30 to 80 years of age
  • Receiving hemodialysis at least 12 months and less than 5 years
  • Pre-dialysis systolic blood pressure was more than 160 mmHg, or more than 150 mmHg if the patients received antihypertensive agents.

Exclusion Criteria:

  • Use of angiotensin receptor blocker or angiotensin converting enzyme inhibitor
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00530595

Sponsors and Collaborators
Saitama Medical University
Investigators
Study Director: Hiromichi Suzuki, MD, PhD Department of Nephrology, Saitama Medical University
  More Information

No publications provided by Saitama Medical University

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

ClinicalTrials.gov Identifier: NCT00530595     History of Changes
Other Study ID Numbers: S-01
Study First Received: September 13, 2007
Last Updated: September 14, 2007
Health Authority: Japan: Institutional Review Board

Keywords provided by Saitama Medical University:
hemodialysis

Additional relevant MeSH terms:
Cardiovascular Diseases
Losartan
Candesartan
Candesartan cilexetil
Valsartan
Angiotensin Receptor Antagonists
Anti-Arrhythmia Agents
 Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on May 21, 2013